(104 days)
Not Found
No
The device description details a mechanical pen injector with a memory function for tracking the last dose and time elapsed. There is no mention of AI or ML in the description of its operation or features.
No.
The device is an insulin pen injector, which is used to administer medication (insulin), but it does not directly provide therapy itself. It is a drug delivery device.
No
The device is an insulin pen injector designed for self-administration of insulin, not for diagnosing a medical condition. While it has a memory function for tracking the last dose and time elapsed, this information aids in insulin management rather than diagnosis.
No
The device description clearly details a physical pen injector with mechanical components for insulin delivery and a memory function with a liquid crystal display. It is not solely software.
No, this device is not an IVD (In Vitro Diagnostic).
Here's why:
- IVD Definition: In Vitro Diagnostics are medical devices used to examine specimens taken from the human body (like blood, urine, or tissue) to provide information for diagnosis, monitoring, or screening.
- NovoPen Echo Function: The NovoPen Echo is a device used to deliver a substance (insulin) into the body. It does not analyze any biological samples or provide diagnostic information based on those samples. Its function is purely mechanical delivery and dose tracking.
The description clearly states its purpose is for the "self-injection of a desired dose of insulin" and describes the mechanical process of setting and injecting the dose. The memory function tracks dose history, but this is for patient information and adherence, not for in vitro diagnostic testing.
N/A
Intended Use / Indications for Use
The NovoPen Echo® is a re-useable pen injector designed for single patient use by diabetics for the self-injection of a desired dose of insulin. The pen injector uses PenFill® 3 mL cartridge of NovoLog®, 100 units/mL (U-100) finesulin aspart injection], Fiasp® 100 units/mL (U-100) [insulin aspart injection], and a single use detachable and disposable pen needle (supplied separately). The pen injector allows the user to dial the desired dose from 0.5 to 30 units in 0.5 unit increments.
Product codes
FMF
Device Description
The NovoPen Echo® is a reusable mechanical pen-injector capable of injecting a dose of up to 30 units of insulin, in 0.5 unit increments, from a NovoLog 3 mL PenFill® cartridge. The memory function enables the user of the device to see the quantity of last given dose and hours that have passed since last dose. The operation of the pen-injection of insulin is entirely independent of the operation of the memory function. The intended dose is mechanically set by rotating a dose button. The insulin is injected by depressing the dose button which via mechanical coupling causes the piston in the insulin cartridge to move forward thereby expelling the intended dose. The device has a memory function and liquid crystal display that allows the user to review the units of the last dose and the number of hours that have elapsed since the last dose was taken. Rotation of the dose button during dose setting causes a sensor to rotate within a coded cylinder. The movement detected by this sensor is stored for later display on the liquid crystal display in the dosage selector module as the number of units injected.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
Not Found
Indicated Patient Age Range
Not Found
Intended User / Care Setting
single patient use by diabetics for the self-injection
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies
Device Verification Tests confirm that the NovoPen Echo meets the requirements of ISO11608-1 Needle-based injection systems for medical use - Requirement and test methods - Part 1: Needle based injection systems.
Novo Nordisk proposes to expand the currently approved intended use for NovoPen Echo to include the use of Fiasp® (insulin aspart injection) 3mL PenFill® cartridges. Therefore, the dose accuracy performance test of the Fiasp® (insulin aspart injection) 3 mL PenFill® cartridges with NovoPen Echo® was performed which meets the requirements of ISO11608-1:2014.
No clinical testing was provided or required.
Key Metrics
Not Found
Predicate Device(s)
K162602 NovoPen Echo®
Reference Device(s)
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information
Not Found
§ 880.5860 Piston syringe.
(a)
Identification. A piston syringe is a device intended for medical purposes that consists of a calibrated hollow barrel and a movable plunger. At one end of the barrel there is a male connector (nozzle) for fitting the female connector (hub) of a hypodermic single lumen needle. The device is used to inject fluids into, or withdraw fluids from, the body.(b)
Classification. Class II (performance standards).
0
Image /page/0/Picture/0 description: The image contains the logo of the U.S. Food and Drug Administration (FDA). On the left is the Department of Health & Human Services logo. To the right of that is the FDA logo, which is a blue square with the letters "FDA" in white. To the right of the blue square is the text "U.S. FOOD & DRUG ADMINISTRATION" in blue.
December 17, 2018
Novo Nordisk Inc. Elizabeth D'amato Director, Regulatory Affairs 800 Scudders Mill Rd Plainsboro, New Jersey 08536
Re: K182387
Trade/Device Name: NovoPen Echo Regulation Number: 21 CFR 880.5860 Regulation Name: Piston Syringe Regulatory Class: Class II Product Code: FMF Dated: November 26, 2018 Received: November 27, 2018
Dear Elizabeth D'amato:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database located at https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part
1
801); medical device reporting of medical device-related adverse events) (21 CFR 803) for devices or postmarketing safety reporting (21 CFR 4, Subpart B) for combination products (see https://www.fda.gov/CombinationProducts/GuidanceRegulatoryInformation/ucm597488.htm); good manufacturing practice requirements as set forth in the quality systems (OS) regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm.
For comprehensive regulatory information about mediation-emitting products, including information about labeling regulations, please see Device Advice
(https://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/) and CDRH Learn (http://www.fda.gov/Training/CDRHLearn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (http://www.fda.gov/DICE) for more information or contact DICE by email (DICE@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100).
Sincerely,
Alan M.
Stevens -S
Tina Kiang, Ph.D. for Acting Director Division of Anesthesiology, General Hospital, Respiratory, Infection Control, and Dental Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
2
Indications for Use
510(k) Number (if known) K182387
Device Name NovoPen Echo®
Indications for Use (Describe)
The NovoPen Echo® is a re-useable pen injector designed for single patient use by diabetics for the self-injection of a desired dose of insulin. The pen injector uses PenFill® 3 mL cartridge of NovoLog®, 100 units/mL (U-100) finsulin aspart injection], Fiasp® 100 units/mL (U-100) [insulin aspart injection], and a single use detachable and disposable pen needle (supplied separately). The pen injector allows the user to dial the desired dose from 0.5 to 30 units in 0.5 unit increments.
| Type of Use (Select one or both, as applicable) | |
|---|---|
| X Prescription Use (Part 21 CFR 801 Subpart D) | Over-The-Counter Use (21 CFR 801 Subpart C) |
CONTINUE ON A SEPARATE PAGE IF NEEDED.
This section applies only to requirements of the Paperwork Reduction Act of 1995.
DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.
The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:
Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff@fda.hhs.gov
"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."
3
TRADITIONAL 510(K) SUMMARY
| Manufacturer's Name: | Novo Nordisk Inc.
PO Box 846
Plainsboro, NJ 08536 |
|---------------------------------|---------------------------------------------------------------------------------|
| Corresponding Official: | Elizabeth D'Amato
Director, Regulatory Affairs |
| Telephone Number:
E-mail: | 609-919-7789
lizd@novonordisk.com |
| Preparation Date: | December 14, 2018 |
| Trade Name: | NovoPen Echo® |
| Common or Usual Name: | Dial-A-Dose Insulin Delivery Device (Pen Injector) |
| Classification Name and Number: | Piston Syringe
Regulation: 21 CFR 880.5860
Class: II
Product Code: FMF |
| Primary Predicate Device: | K162602 NovoPen Echo® |
Device Description
The NovoPen Echo® is a reusable mechanical pen-injector capable of injecting a dose of up to 30 units of insulin, in 0.5 unit increments, from a NovoLog 3 mL PenFill® cartridge. The memory function enables the user of the device to see the quantity of last given dose and hours that have passed since last dose. The operation of the pen-injection of insulin is entirely independent of the operation of the memory function. The intended dose is mechanically set by rotating a dose button. The insulin is injected by depressing the dose button which via mechanical coupling causes the piston in the insulin cartridge to move forward thereby expelling the intended dose. The device has a memory function and liquid crystal display that allows the user to review the units of the last dose and the number of hours that have elapsed since the last dose was taken. Rotation of the dose button during dose setting causes a sensor to rotate within a coded cylinder. The movement detected by this sensor is stored for later display on the liquid
4
crystal display in the dosage selector module as the number of units injected. The NovoPen Echo® is substantially equivalent to NovoPen Echo® cleared under K162602.
Intended Use
The Intended Use including Indication for Use for the proposed device is as follows: The NovoPen Echo® is a re-useable pen injector designed for single patient use by diabetics for the self-injection of a desired dose of insulin. The pen injector uses PenFill® 3 mL cartridge of NovoLog®, 100 units/mL (U-100) [insulin aspart injection], Fiasp® 100 units/mL (U-100) [insulin aspart injection], and a single use detachable and disposable pen needle (supplied separately). The pen injector allows the user to dial the desired dose from 0.5 to 30 units in 0.5 unit increments.
Substantial Equivalence Discussion
The NovoPen Echo® is substantially equivalent to NovoPen Echo® cleared under K162602 on October 18, 2016.
There are no changes made to the NovoPen Echo® device from the previously cleared NovoPen Echo® (K162602). Intended use, user, and user environment of the NovoPen Echo® are the same for NovoLog® and Fiasp® 3 mL PenFill. Therefore, based on the dose accuracy data with Fiasp® the addition of Fiasp® 3 mL PenFill is not expected to impact the safe and effective use of the NovoPen Echo®. The proposed NovoPen Echo® is substantially equivalent to NovoPen Echo® cleared under K162602.
Discussion of Differences
The purpose for submitting this Traditional 510(k) is to obtain marketing clearance for NovoPen Echo expand the currently approved intended use to include Fiasp® (insulin aspart injection) 3mL PenFill® cartridges.
There have been no changes in the principle of operation, materials, energy source and performance compared with the predicate devices.
Performance Testing
Device Verification Tests confirm that the NovoPen Echo meets the requirements of ISO11608-1 Needle-based injection systems for medical use - Requirement and test methods - Part 1: Needle based injection systems.
Novo Nordisk proposes to expand the currently approved intended use for NovoPen Echo to include the use of Fiasp® (insulin aspart injection) 3mL PenFill® cartridges. Therefore, the dose accuracy performance test of the Fiasp® (insulin aspart injection) 3 mL PenFill® cartridges with NovoPen Echo® was performed which meets the requirements of ISO11608-1:2014.
5
Shelf Life
The NovoPen Echo® has an in-use lifetime of 5 years provided that the pen is taken into use within two years of the production date. The NovoPen Echo® informs the user via the memory display when the pen has reached its end of life.
Clinical Tests
No clinical testing was provided or required.
Conclusions
In conclusion, the results of the testing demonstrate that NovoPen Echo® performs as well as the predicate device.
The results of the testing to standards provide additional evidence that NovoPen Echo® is substantially equivalent to the predicate device, NovoPen Echo®. The differences between NovoPen Echo® and the predicate device do not raise any new performance issues. The differences between NovoPen Echo® and the predicate device do not change the intended use of the product.